Vol. 3 No. 4 (2023)
Reimbursement Reviews

Dupilumab (Dupixent)

decorative image

Published April 18, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dupilumab (Dupixent), 200 mg or 300 mg, single-use syringe, solution for subcutaneous injection.
  • Indication: As an add-on maintenance treatment in patients aged ≥ 6 years with severe asthma with a type 2 or eosinophilic phenotype or oral corticosteroid-dependent asthma.